Drug use linked to better survival in a form of heart failure
At 60 months, survival was 83.5% among users of glucagon-like peptide-1 receptor agonists, versus 57.4% among matched nonusers.
Our read
Populations- Studied:
- Cohort study of adults with confirmed HFpEF, 60 months, against the non-GLP-1 group
- What changed:
- At 60 months, overall survival was 83.5% in the GLP-1 group against 57.4% in the non-GLP-1 group
- Why it’s aging research:
- It studies an intervention with evidence of extending healthy life.
Editor of record: Boris Djordjevic · AgingResearch.News
Adults with confirmed heart failure with preserved ejection fraction were compared in a retrospective observational cohort study using the Mayo Clinic platform. In this condition, the heart pumps out a normal share of its blood with each beat. Researchers matched 6,676 users of drugs called glucagon-like peptide-1 receptor agonists with 6,676 nonusers on baseline characteristics.
Mean ages were 66.9 and 66.5 years, respectively; women made up 49.1% and 47.7%. At 60 months, survival was 83.5% among users and 57.4% among nonusers. The share remaining free of major cardiovascular events was 76.0% versus 52.8%. Drug use was associated with better survival and fewer major cardiovascular events.
Why it matters
For older adults with this form of heart failure, the findings suggest a potential benefit for heart health and metabolism that randomized trials could test.
Caveats
Differences in health or care not captured by the matching could help explain the associations. Both groups were predominantly White, and the findings were reported in a conference abstract.
The paper
Mayo Clinic Arizona; Mayo Clinic
AHA Scientific Sessions 2026 Abstract, Nov 2, 2026
Presented at AHA Scientific Sessions 2026, abstract 15838
Comments
Be the first to comment.